Paper Details

  1. Home
  2. Paper Details

Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.

Author: HassaneinTarek, HowellCharles D, JenkinsTim M, JoshiShobha, LakeJohn, McIntoshJoe, SherLinda, TangShande, TerraultNorah A, VargasHugo

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A phase II, multicenter study investigated the efficacy and safety of avatrombopag in patients with thrombocytopenia secondary to cirrhosis undergoing elective invasive procedures. The study found that avatrombopag was generally well-tolerated and increased platelet counts, but one patient developed portal vein thrombosis.
Paper Details　
Original Abstract of the Article :
BACKGROUND & AIMS: This is a phase II multicentre study to investigate the efficacy and safety of avatrombopag (E5501), an investigational second-generation thrombopoietin receptor agonist, administered one week prior to elective procedures in patients with thrombocytopenia secondary to cirrhosis. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jhep.2014.07.007

データ提供：米国国立医学図書館（NLM）

Avatrombopag: A Potential Solution for Thrombocytopenia in Cirrhosis Patients

This study explores the use of avatrombopag, a thrombopoietin receptor agonist, in patients with cirrhosis and thrombocytopenia, a condition characterized by low platelet counts. The researchers conducted a phase II clinical trial to evaluate the safety and effectiveness of avatrombopag in increasing platelet counts in these patients undergoing elective procedures.

Avatrombopag: Increasing Platelet Counts in Cirrhosis Patients

The study found that avatrombopag, administered one week prior to elective procedures, was generally well-tolerated and effectively increased platelet counts in patients with cirrhosis and thrombocytopenia. This finding could have significant implications for improving the safety of elective procedures for these patients. It's like finding a way to safely navigate a treacherous desert terrain, ensuring a smoother and more successful journey.

Navigating the Challenges of Cirrhosis and Thrombocytopenia

The study's findings provide valuable insights into the management of thrombocytopenia in patients with cirrhosis. It offers a potential solution for addressing a common complication that can pose risks during elective procedures. This research highlights the importance of finding innovative treatments for complex medical conditions, much like discovering a new and reliable source of water in a parched desert.

Dr.Camel's Conclusion

This study offers hope for patients with cirrhosis and thrombocytopenia. It suggests that avatrombopag could be a safe and effective treatment for increasing platelet counts, potentially improving the safety and outcomes of elective procedures. It's like discovering a magical oasis in the desert, offering respite and healing for those navigating the challenges of cirrhosis and thrombocytopenia.

Date :
  1. Date Completed 2015-08-25
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

25048952

DOI: Digital Object Identifier

10.1016/j.jhep.2014.07.007

Related Literature

Article Analysis
・Effects of avatrombopag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.